top of page
Our Pipeline
Dragonfly’s novel immune engagers potently kill disease targets to treat autoimmune and inflammatory diseases, cancers and other diseases, with a uniquely favorable safety profile.
Pivotal
Discovery
Preclinical
Phase 1
Phase 2
DF5112 (CCR6)
​
​
Th17 depleter; HS, SSc, PsA, RA and PBC
DF2511 (CD19)
SLE, LN, NMOSD
Program (Target)
Primary Indication(s)
DF8203 (FAP)
RA, IPF, SS-ILD
DF2211 (BAFFR)
Sjogren's, PV, BP, LN
DF5201 (CD52)
SLE, LN, SSc, IIM, RA, MS
DF3100 (BCMA)
AL Amyloidosis, MG, SSc
bottom of page